Prognostic value and risk stratification of residual disease in patients with incidental gallbladder cancer

Emilio Ramos, Nuria Lluis, Laura Llado, Jaume Torras, Juli Busquets, Antoni Rafecas, Teresa Serrano, Kristel Mils, David Leiva, Joan Fabregat, Emilio Ramos, Nuria Lluis, Laura Llado, Jaume Torras, Juli Busquets, Antoni Rafecas, Teresa Serrano, Kristel Mils, David Leiva, Joan Fabregat

Abstract

Background and aim: Given their poor prognosis, patients with residual disease (RD) in the re-resection specimen of an incidental gallbladder carcinoma (IGBC) could benefit from a better selection for surgical treatment. The Gallbladder Cancer Risk Score (GBRS) has been proposed to preoperatively identify RD risk more precisely than T-stage alone. The aim of this study was to assess the prognostic value of RD and to validate the GBRS in a retrospective series of patients.

Material and methods: A prospectively collected database including 59 patients with IGBC diagnosed from December 1996 to November 2015 was retrospectively analyzed. Three locations of RD were established: local, regional, and distant. The effect of RD on overall survival (OS) was analyzed with the Kaplan-Meier method. To identify variables associated with the presence of RD, characteristics of patients with and without RD were compared using Fisher's exact test. The relative risk of RD associated with clinical and pathologic factors was studied with a univariate logistic regression analysis.

Results: RD was found in 30 patients (50.8%). The presence of RD in any location was associated with worse OS (29% vs. 74.2%, p = 0.0001), even after an R0 resection (37.7% vs 74.2%, p = 0.003). There was no significant difference in survival between patients without RD and with local RD (74.2% vs 64.3%, p = 0.266), nor between patients with regional RD and distant RD (16.1% vs 20%, p = 0.411). After selecting patients in which R0 resection was achieved (n = 44), 5-year survival rate for patients without RD, local RD, and regional RD was, respectively, 74.2%, 75%, and 13.9% (p = 0.0001). The GBRS could be calculated in 25 cases (42.3%), and its usefulness to predict the presence of regional or distant RD (RDRD) was confirmed (80% in high-risk patients and 30% in intermediate risk p = 0.041).

Conclusion: RDRD, but not local RD, represents a negative prognostic factor of OS. The GBRS was useful to preoperatively identify patients with high risk of RDRD. An R0 resection did not improve OS of patients with regional RD.

Keywords: Hepatobiliary neoplasms; Incidental gallbladder Cancer; Residual disease; Risk score; Staging; Surgical treatment.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Long-term survival after an R0 resection (n = 44) for patients without RD (n = 29), with local RD (n = 6) and with regional RD (n = 9)

References

    1. Pawlik T, Gleisner AL, Vigano L, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg. 2007;11:1478–1487. doi: 10.1007/s11605-007-0309-6.
    1. Shukla P.J., Barreto G., Kakade A., Shrikhande S.V. Revision surgery for incidental gallbladder cancer: factors influencing operability and further evidence for T1b tumours. HPB. 2008;10(1):43–47. doi: 10.1080/13651820701867794.
    1. Butte JM, Waugh E, Meneses M, et al. Incidental gallbladder cancer: analysis of surgical findings and survival. J Surg Oncol. 2010;102:620–625. doi: 10.1002/jso.21681.
    1. Fuks D, Regimbeau JM, Le Treut YP, et al. Incidental gallbladder cancer by the AFC-GBC-2009 Study Group. World J Surg. 2011;35:1887–1897. doi: 10.1007/s00268-011-1134-3.
    1. Ito H, Ito K, D’Angelica M, et al. Accurate staging for gallbladder cancer implications for surgical therapy and pathological assessment. Ann Surg. 2011;254:320–325. doi: 10.1097/SLA.0b013e31822238d8.
    1. Aloia TA, Jarufe N, Javle M, et al. Gallbladder cancer: expert consensus statement. HPB (Oxford) 2015;17:681–690. doi: 10.1111/hpb.12444.
    1. Creasy JM, Goldman DA, Gonen M, et al. Predicting residual disease in incidental gallbladder cancer: risk stratification for modified treatment strategies. J Gastrointest Surg. 2017;21:1254–1261. doi: 10.1007/s11605-017-3436-8.
    1. Vinuela E, Vega EA, Yamashita S, et al. Incidental gallbladder cancer: residual cancer discovered at oncologic extended resection determines outcome: a Reportfrom high- and low-incidence countries. Ann Surg Oncol. 2017;24:2334–2343. doi: 10.1245/s10434-017-5859-6.
    1. Duffy A, Capanu M, Abou-Alfa GK, et al. Gallbladder cancer (GBC): 10-year experience at memorial Sloan-Kettering Cancer Centre (MSKCC) J Surg Oncol. 2008;98:485–489. doi: 10.1002/jso.21141.
    1. Lendoire JC, Gil L, Duek F, et al. Relevance of residual disease after liver resection for incidentalgallbladder cancer. HPB. 2012;14:548–553. doi: 10.1111/j.1477-2574.2012.00498.x.
    1. Watson H, Dasari B, Wyatt J, et al. Does a second resection provide a survival benefit in patients diagnosed with incidental T1b/T2 gallbladder cancer following cholecystectomy? HPB (Oxford) 2017;19:104–107. doi: 10.1016/j.hpb.2016.11.006.
    1. Butte JM, Kingham TP, Gönen M, et al. Residual disease predicts outcomes after definitive resection for incidental gallbladder cancer. J Am Coll Surg. 2014;219:416–429. doi: 10.1016/j.jamcollsurg.2014.01.069.
    1. Gil L, Lendoire J, Duek F, et al. Radical surgery for incidental gallbladder cancer: the value of a deferred pathological finding of residual disease. Cir Esp. 2014;92(3):168–174. doi: 10.1016/j.ciresp.2013.11.010.
    1. de Aretxabala X, Oppliger F, Solano N, et al. Laparoscopic management of incidental gallbladder cancer. Surg Endosc. 2018;32:4251–4255. doi: 10.1007/s00464-018-6173-5.
    1. Ausania F, Tsirlis T, White AS, et al. Incidental pT2-T3 gallbladder cancer after a cholecystectomy: outcome of staging at 3 months prior to a radical resection. HPB. 2013;15:633–637. doi: 10.1111/hpb.12032.
    1. Ethun CG, Postlewait LM, Le N, et al. A novel pathology-based preoperative risk score to predict locoregional residual and distant disease and survival for incidental gallbladder cancer: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. Ann Surg Oncol. 2017;24:1343–1135. doi: 10.1245/s10434-016-5637-x.
    1. Endo I, Shimada H, Takimoto A, et al. Microscopic liver metastasis: prognostic factor for patients with pT2 gallbladder carcinoma. World J Surg. 2004;28:692–696. doi: 10.1007/s00268-004-7289-4.
    1. Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg. 2015;261:733–739. doi: 10.1097/SLA.0000000000000728.
    1. Horkoff MJ, Ahmed Z, Xu Y, Sutherlan FR et al. Adverse outcomes after bile spillage in incidental gallbladder cancers: a population-based study. Ann Surg. 2019. doi: . [Epub ahead of print].
    1. Cavallaro A, Piccolo G, Di Vita M, et al. Managing the incidentally detected gallbladder cancer: algorithms and controversies. Int J Surg. 2014;12(Suppl 2):S108–S119. doi: 10.1016/j.ijsu.2014.08.367.
    1. Chatelain D, Fuks D, Farges O, et al. Pathology report assessment of incidental gallbladder carcinoma diagnosed from cholecystectomy specimens: results of a French multicentre survey. Dig and Liver Dis. 2013;45:1056–1060. doi: 10.1016/j.dld.2013.07.004.
    1. Goel M, Tamhankar A, Rangarajan V, et al. Role of PET CT scan in redefining treatment of incidental gall bladder carcinoma. J Surg Oncol. 2016;113:6562–6658. doi: 10.1002/jso.24198.
    1. Søreide K, Guest RV, Harrison EM, et al. Systematic review of management of incidental gallbladder cancer after cholecystectomy. Br J Surg. 2019;106(1):32–45. doi: 10.1002/bjs.11035.
    1. Cherkassky L, Jarnagin W. Selecting treatment sequence for patients with incidental gallbladder cancer: a neoadjuvant approach versus upfront surgery. Updat Surg. 2019;71(2):217–225. doi: 10.1007/s13304-019-00670-z.
    1. Bizama C, García P, Espinoza JA, et al. Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev. 2015;41(3):222–234. doi: 10.1016/j.ctrv.2015.01.003.
    1. Javle M, Rashid A, Churi C, et al. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014;45(4):701–708. doi: 10.1016/j.humpath.2013.11.001.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner